Electrostatic charge conversion processes in engineered tumor-identifying polypeptides for targeted chemotherapy

Biomaterials. 2012 Feb;33(6):1884-93. doi: 10.1016/j.biomaterials.2011.11.026. Epub 2011 Dec 7.

Abstract

One of the current challenges in cancer chemotherapy is the ultra-sensitive identification of in vivo tumors. Herein, we report a new class of tumor-identifying polypeptides that can home in on in vivo tumors via an electrostatic charge conversion process occurring in the acidic milieu of a verity of tumors, which can be distinguished from receptor-interacting conventional tumor-homing peptides. We exploit the chemical coupling between polypeptides and therapeutic objects (drugs or particles) to carry out an antitumor study in nude mice, and find a significant increase in the efficiency of polypeptide-tagged objects in tumor uptake and inhibition, which is more significant than any known tumor-homing peptide system thus far developed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Female
  • HeLa Cells
  • Humans
  • Hydrogen-Ion Concentration
  • Melanoma, Experimental
  • Mice
  • Mice, Nude
  • Models, Chemical
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Peptides / chemistry*
  • Photochemotherapy / methods
  • Static Electricity
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Peptides